Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and who are overweight. Following a positive end-of-Phase II meeting, Novo Nordisk shared that regulatory authorities have approved the therapy to proceed.

Novo Nordisk is likely to draw investor attention on Monday after the company said it is moving forward with the oral and subcutaneous forms of its investigational obesity drug amycretin following early clinical studies showing up to 24.